Clinical Trial Update: QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

View source ↗

Summary

Clinical trial update for QuantifyHER, a quantitative immunofluorescence and/or RT-qPCR method to measure HER2 in HER2-low metastatic breast cancer, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: HER2-positive Metastatic Breast Cancer | Status: RECRUITING